Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: Factors influencing on international application of evidence-based guidelines

International Journal of Cardiology

Volumn 118, Issue 1, 2007, Pages 88-96

  Hayashino, Yasuaki ^a   Shimbo, Takuro ^b   Tsujii, Satoru ^c   Ishii, Hitoshi ^c   Kondo, Hirokazu ^a   Nakamura, Tsukasa ^d   Nagata Kobayashi, Shizuko ^a   Fukui, Tsuguya ^e  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c TENRI HOSPITAL   (Japan)

^d SHIMANE PREFECTURAL CENTRAL HOSPITAL   (Japan)

^e ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

Author keywords

Cost effectiveness analysis; Diabetes mellitus; International comparison; Screening strategy; Silent myocardial ischemia

Indexed keywords

ADULT; AGE; AGED; ARTICLE; ATHEROSCLEROSIS; COHORT ANALYSIS; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; ECHOCARDIOGRAPHY; EVIDENCE BASED MEDICINE; EXERCISE ELECTROCARDIOGRAPHY; FEMALE; GENDER; HIGH RISK PATIENT; HUMAN; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SCREENING TEST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; UNITED STATES;

AGED; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EVIDENCE-BASED MEDICINE; EXERCISE TEST; FEMALE; HUMANS; JAPAN; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINES; PREVALENCE; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34047168380     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.03.086     Document Type: Article

References (63)

1. Statistics and information Department, Ministers Secretariat, Ministry of Health and Welfare, patient behavioral survey 1999 (2001), Ministry of Health and Welfare, Tokyo, Japan [in Japanese]
2. American Heart Association. Heart Disease and Stroke Statistics-2004 Update.
3. Ministry of Health and Welfare. 2002 survey on diabetes (2003), Ministry of Health and Welfare, Tokyo, Japan [in Japanese]
4. Jacoby R.M., and Nesto R.W. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol 20 3 (1992) 736-744
5. Fava S., Azzopardi J., Muscat H.A., and Fenech F.F. Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care 16 12 (1993) 1615-1618
6. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February 1998, Miami, Florida. American Diabetes Association. Diabetes Care 21 9 (1998) 1551-1559
7. Goldie S.J. Health economics and cervical cancer prevention: a global perspective. Virus Res. 89 2 (2002) 301-309
8. Hayashino Y., Nagata-Kobayashi S., Morimoto T., Maeda K., Shimbo T., and Fukui T. Cost effectiveness of screening for coronary artery disease in asymptomatic patients with type 2 diabetes and additional atherogenic risk factors. J Gen Intern Med 19 (2004) 1181-1191
9. Cohn P.F. Silent myocardial ischemia. Ann Intern Med 109 4 (1988) 312-317
10. Sonnenberg F.A., and Beck J.R. Markov models in medical decision making: a practical guide. Med Decis Making 13 4 (1993) 322-338
11. Weinstein M.C., Coxson P.G., Williams L.W., Pass T.M., Stason W.B., and Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health 77 11 (1987) 1417-1426
12. Nakamura T., Tsubono Y., Kameda-Takemura K., et al. Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees: a case-control study. Jpn Circ J 65 1 (2001) 11-17
13. D'Agostino Sr. R.B., Grundy S., Sullivan L.M., and Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286 2 (2001) 180-187
14. Anderson K.M., Odell P.M., Wilson P.W., and Kannel W.B. Cardiovascular disease risk profiles. Am Heart J 121 1 Pt 2 (1991) 293-298
15. Nomura H., Koizumi J., Hayashi T., Matsukura T., and Mabuchi H. Annual meeting for the Japanese society of general medicine, Kagawa, Japan (2002) 43 [in Japanese]
16. Koizumi J., Shimizu M., Miyamoto S., Origasa H., and Mabuchi H. Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT). J Atheroscler Thromb 9 5 (2002) 251-259
17. Hunink M.G., Goldman L., Tosteson A.N., et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA 277 7 (1997) 535-542
18. Airaksinen K.E. Silent coronary artery disease in diabetes-a feature of autonomic neuropathy or accelerated atherosclerosis?. Diabetologia 44 2 (2001) 259-266
19. Chaitman B.R., Bourassa M.G., Davis K., et al. Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS). Circulation 64 2 (1981) 360-367
20. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 20 (1995) 1301-1307
21. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 9374 (2003) 2005-2016
22. Haffner S.M. Dyslipidemia management in adults with diabetes. Diabetes Care 27 Suppl 1 (2004) S68-S71
23. Shihara M., Tsutsui H., Tsuchihashi M., Tada H., Kono S., and Takeshita A. In-hospital and one-year outcomes for patients undergoing percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 90 9 (2002) 932-936
24. Mastoor M., Iqbal U., Pinnow E., and Lindsay Jr. J. Ethnicity does not affect outcomes of coronary angioplasty. Clin Cardiol 23 5 (2000) 379-382
25. Gianrossi R., Detrano R., Mulvihill D., et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation 80 1 (1989) 87-98
26. Statistics and information Department, Ministers Secretariat, Ministry of Health and Welfare, patient survey 1999 (2001), Ministry of Health and Welfare, Tokyo, Japan [in Japanese]
27. Yusuf S., Zucker D., Peduzzi P., et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 344 8922 (1994) 563-570
28. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 308 6921 (1994) 81-106
29. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 18 (1998) 1837-1847
30. Menotti A., Blackburn H., Seccareccia F., et al. The relation of chronic diseases to all-cause mortality risk-the seven countries study. Ann Med 29 2 (1997) 135-141
31. Mark D.B., Nelson C.L., Califf R.M., et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation 89 5 (1994) 2015-2025
32. Pocock S.J., Henderson R.A., Rickards A.F., et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet 346 8984 (1995) 1184-1189
33. Sanmuganathan P.S., Ghahramani P., Jackson P.R., Wallis E.J., and Ramsay L.E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85 3 (2001) 265-271
34. Gaspoz J.M., Coxson P.G., and Goldman P.A. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 346 23 (2002) 1800-1806
35. Johnson L.W., Lozner E.C., and Johnson S. Coronary arteriography 1984-1987: a report of the Registry of the Society for Cardiac Angiography and Interventions. I. Results and complications. Cathet Cardiovasc Diagn 17 1 (1989) 5-10
36. Holmes Jr. D.R., Holubkov R., and Vlietstra R.E. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol 12 5 (1988) 1149-1155
37. Yusuf S., Zucker D., and T.C.C. Ten-year results of the randomized controlled trials of coronary artery bypass graft surgery: tabular data complied by the collaborative effort of the original trial investigators. Part 1 of 2. Online J Curr Clin Trials 14 (1994) [document no.144]
38. Yusuf S., Zucker D., and T.C.C. Ten-year results of the randomized controlled trials of coronary artery bypass graft surgery: tabular data complied by the collaborative effort of the original trial investigators. Part 2 of 2. Online J Curr Clin Trials 14 (1994) [document no.145]
39. Hannan E.L., Kilburn Jr. H., O'Donnell J.F., Lukacik G., and Shields E.P. Adult open heart surgery in New York State. An analysis of risk factors and hospital mortality rates. JAMA 264 21 (1990) 2768-2774
40. Finkler S.A. The distinction between cost and charges. Ann Intern Med 96 1 (1982) 102-109
41. Quality-of-life Policy Bureau. The report from working party for medical costs. announcement in 07 March, 2001 Available from URL:http://www5.cao.go.jp/seikatsu/2001/0307iryou-houkoku/menu.html [in Japanese].
42. Division of Medicine, Department of Insurance, Japanese Ministry of Health and Welfare. Interpretation of the social insurance reimbursement table (2000), Research Institute of Social Insurance, Tokyo (in Japanese)
43. Nagata-Kobayashi S., Shimbo T., and Fukui T. Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women. J Bone Miner Metab 20 6 (2002) 350-357
44. Ministry of Health, Labour and Welfare. White Paper on the Labour Economy 2003 Japan Institute of Labour, Tokyo [in Japanese].
45. Statistics Bureau (2003) Japan Statistical Yearbook, 2004. Ministry of Public Management, Home Affairs, Posts, and Telecommunications, Tokyo. [in Japanese].
46. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., and Russell L.B. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276 15 (1996) 1253-1258
47. Torrance G.W. Preferences for health states: a review of measurement methods. Mead Johnson Symp Perinat Dev Med 20 (1982) 37-45
48. Torrance G.W., Thomas W.G., and Sackett D.L. A utility maximization model for evaluation of health care programs. Health Serv Res 7 (1972) 118-133
49. Fleischmann K.E., Hunink M.G., Kuntz K.M., and Douglas P.S. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA 280 10 (1998) 913-920
50. Statistics and Information Department, Ministers Secretariat, Ministry of Health and Welfare. Abridged life table 2003 (2003), Ministry of Health and Welfare, Tokyo, Japan [in Japanese]
51. Tsuji I., Fukao A., Sugawara N., Shoji T., Kuwajima I., and Hisamichi S. Cost-effectiveness analysis of screening for gastric cancer in Japan. Tohoku J Exp Med 164 4 (1991) 279-284
52. Okubo I., Glick H., Frumkin H., and Eisenberg J.M. Cost-effectiveness analysis of mass screening for breast cancer in Japan. Cancer 67 8 (1991) 2021-2029
53. Reilly B.M. The essence of EBM. BMJ 329 7473 (2004) 991-992
54. Morimoto T., Fukui T., Lee T.H., and Matsui K. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med 117 7 (2004) 459-468
55. Vijan S., Hofer T.P., and Hayward R.A. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 283 7 (2000) 889-896
56. Boulware L.E., Jaar B.G., Tarver-Carr M.E., Brancati F.L., and Powe N.R. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 290 23 (2003) 3101-3114
57. Frame P.S., Fryback D.G., and Patterson C. Screening for abdominal aortic aneurysm in men ages 60 to 80 years. A cost-effectiveness analysis. Ann Intern Med 119 5 (1993) 411-416
58. Yeo W.W., and Yeo K.R. Predicting CHD risk in patients with diabetes mellitus. Diabet Med 18 5 (2001) 341-344
59. Stevens R.J., Kothari V., Adler A.I., and Stratton I.M. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 101 6 (2001) 671-679
60. Song S.H., and Brown P.M. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med 21 3 (2004) 238-245
61. Fox C.S., Sullivan L., D'Agostino Sr. R.B., and Wilson P.W. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diabetes Care 27 3 (2004) 704-708
62. Hunink M., Glasziou P., Siegel J., et al. Decision making in health and medicine: integrating evidence and values (2001), Cambridge University Press, Cambridge
63. Alexander C.M., Landsman P.B., and Teutsch S.M. Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol 86 9 (2000) 897-902